{"id":"camostat","rwe":[{"pmid":"41755626","year":"2026","title":"SARS-CoV-2 infects human primary cytotrophoblasts mainly through a non-canonical entry route.","finding":"","journal":"Molecular human reproduction","studyType":"Clinical Study"},{"pmid":"41700320","year":"2026","title":"Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.","finding":"","journal":"The Journal of infectious diseases","studyType":"Clinical Study"},{"pmid":"41601680","year":"2025","title":"SARS-CoV-2 evolution enhances endocytic uptake while preserving TMPRSS2-dependent fusion.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41596695","year":"2026","title":"A Nasal Spray Combining Camostat with a Natural Polysaccharide for the Prevention of Viral Infection via Nasal Mucosal Barrier Formation and Entry Inhibition.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41319340","year":"2026","title":"Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas.","finding":"","journal":"ChemMedChem","studyType":"Clinical Study"}],"tags":[{"label":"camostat","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Serine protease hepsin","category":"target"},{"label":"HPN","category":"gene"},{"label":"PRSS1","category":"gene"},{"label":"TMPRSS2","category":"gene"},{"label":"B02AB04","category":"atc"},{"label":"Active","category":"status"},{"label":"Gastro-esophageal reflux disease with esophagitis","category":"indication"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"},{"label":"Serine Proteinase Inhibitors","category":"pharmacology"},{"label":"Trypsin Inhibitors","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["camostat monomethanesulfonate","camostat","camostat mesilate","camostat mesylate"],"offLabel":[],"synonyms":["camostat monomethanesulfonate","camostat","camostat mesilate","camostat mesylate"],"timeline":[],"ecosystem":[{"indication":"Gastro-esophageal reflux disease with esophagitis","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Serine protease hepsin","targets":[{"gene":"HPN","source":"DrugCentral","target":"Serine protease hepsin","protein":"Serine protease hepsin"},{"gene":"PRSS1","source":"DrugCentral","target":"Trypsin-1","protein":"Trypsin-1"},{"gene":"TMPRSS2","source":"DrugCentral","target":"Transmembrane protease serine 2","protein":"Transmembrane protease serine 2"},{"gene":"KLK1","source":"DrugCentral","target":"Kallikrein-1","protein":"Kallikrein-1"},{"gene":"SLC47A1","source":"DrugCentral","target":"Multidrug and toxin extrusion protein 1","protein":"Multidrug and toxin extrusion protein 1"},{"gene":"SLC47A2","source":"DrugCentral","target":"Multidrug and toxin extrusion protein 2","protein":"Multidrug and toxin extrusion protein 2"},{"gene":"SLC22A2","source":"DrugCentral","target":"Solute carrier family 22 member 2","protein":"Solute carrier family 22 member 2"},{"gene":"F2","source":"DrugCentral","target":"Prothrombin","protein":"Prothrombin"},{"gene":"HGFAC","source":"DrugCentral","target":"Hepatocyte growth factor activator","protein":"Hepatocyte growth factor activator"}],"modality":"Small Molecule","drugClass":"camostat","explanation":"Think of CAMOSTAT like a key that locks up a specific enzyme, called hepsin, which is involved in the breakdown of tissues and the promotion of inflammation. By blocking hepsin, CAMOSTAT helps to reduce inflammation and tissue damage, which can help to alleviate symptoms of gastro-esophageal reflux disease with esophagitis. This can lead to improved healing and reduced discomfort for patients.","oneSentence":"CAMOSTAT works by blocking the activity of hepsin, a protease that contributes to inflammation and tissue damage.","technicalDetail":"CAMOSTAT is a reversible, competitive inhibitor of hepsin, a type II transmembrane serine protease involved in the regulation of inflammation and tissue remodeling."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/471","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CAMOSTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CAMOSTAT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:08:22.629208","biosimilars":[],"competitors":[{"drugName":"aprotinin","drugSlug":"aprotinin","fdaApproval":"1993-12-29","relationship":"same-class"}],"genericName":"camostat","indications":{"approved":[{"name":"Gastro-esophageal reflux disease with esophagitis","source":"DrugCentral","snomedId":266433003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"aprotinin","brandName":"aprotinin","genericName":"aprotinin","approvalYear":"1993","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04321096","phase":"PHASE1,PHASE2","title":"The Impact of Camostat Mesilate on COVID-19 Infection","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2020-04-04","conditions":["Corona Virus Infection"],"enrollment":206,"completionDate":"2023-05-01"},{"nctId":"NCT06794593","phase":"PHASE2","title":"Effect Camostat for Kidney Protection in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-21","conditions":["Chronic Kidney Disease(CKD)"],"enrollment":40,"completionDate":"2027-02-28"},{"nctId":"NCT05474664","phase":"PHASE2","title":"Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2022-10-03","conditions":["Fontan Operation","Protein-Losing Enteropathy","Camostat Mesylate"],"enrollment":19,"completionDate":"2024-10-08"},{"nctId":"NCT04470544","phase":"PHASE2","title":"Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Alan Bryce","startDate":"2020-07-28","conditions":["Severe Acute Respiratory Syndrome"],"enrollment":100,"completionDate":"2022-01-20"},{"nctId":"NCT04625114","phase":"PHASE2","title":"The Potential of Camostat in COVID-19","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2020-11-04","conditions":["Covid19"],"enrollment":108,"completionDate":"2022-07-12"},{"nctId":"NCT04518410","phase":"PHASE2,PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":["Coronavirus","Covid19"],"enrollment":4044,"completionDate":"2023-06-20"},{"nctId":"NCT04451083","phase":"PHASE1","title":"Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-07-01","conditions":["Healthy Volunteers"],"enrollment":14,"completionDate":"2020-08-17"},{"nctId":"NCT04657497","phase":"PHASE3","title":"A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-11-09","conditions":["SARS-CoV-2 Infection (COVID-19)"],"enrollment":155,"completionDate":"2021-04-09"},{"nctId":"NCT04455815","phase":"PHASE2","title":"A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)","status":"TERMINATED","sponsor":"Cancer Research UK","startDate":"2020-09-23","conditions":["COVID-19 Infection"],"enrollment":34,"completionDate":"2022-03-03"},{"nctId":"NCT04652765","phase":"PHASE1","title":"Camostat With Bicalutamide for COVID-19","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-02-03","conditions":["Covid19","SARS-CoV Infection","Coronavirus Infection"],"enrollment":6,"completionDate":"2021-09-15"},{"nctId":"NCT04713176","phase":"PHASE3","title":"Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-02-02","conditions":["Severe COVID-19"],"enrollment":240,"completionDate":"2022-12-09"},{"nctId":"NCT04662086","phase":"PHASE2","title":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-23","conditions":["Covid19"],"enrollment":122,"completionDate":"2023-02-02"},{"nctId":"NCT04662073","phase":"PHASE2","title":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-04-23","conditions":["Covid19"],"enrollment":2,"completionDate":"2022-03-04"},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":["Covid19","SARS-CoV2 Infection"],"enrollment":43,"completionDate":"2023-01-10"},{"nctId":"NCT04721535","phase":"PHASE3","title":"A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-06-07","conditions":["Covid19","SARS-COV-2 Infection"],"enrollment":9,"completionDate":"2021-10-06"},{"nctId":"NCT04782505","phase":"PHASE1","title":"Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-03-12","conditions":["Healthy"],"enrollment":61,"completionDate":"2021-06-28"},{"nctId":"NCT04730206","phase":"PHASE3","title":"The DAWN Antivirals Trial for Ambulatory COVID-19 Patients","status":"TERMINATED","sponsor":"KU Leuven","startDate":"2021-06-15","conditions":["Covid19","SARS-CoV Infection"],"enrollment":44,"completionDate":"2022-07-13"},{"nctId":"NCT04521296","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-09-11","conditions":["Mild to Moderate COVID-19"],"enrollment":432,"completionDate":"2022-03-18"},{"nctId":"NCT04524663","phase":"PHASE2","title":"Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-12-19","conditions":["Covid19"],"enrollment":49,"completionDate":"2021-05-15"},{"nctId":"NCT04435015","phase":"PHASE1,PHASE2","title":"The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2021-11","conditions":["Coagulopathy","Cardiovascular Complication","COVID-19"],"enrollment":0,"completionDate":"2021-12-31"},{"nctId":"NCT04353284","phase":"PHASE2","title":"Camostat Mesylate in COVID-19 Outpatients","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-06-09","conditions":["COVID-19"],"enrollment":70,"completionDate":"2021-04-22"},{"nctId":"NCT04681430","phase":"PHASE2","title":"Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2021-01-08","conditions":["Corona Virus Infection","SARS-CoV-2 Infection","SARS-CoV-2 PCR Test Positive","SARS-CoV-2 Acute Respiratory Disease"],"enrollment":22,"completionDate":"2021-10-29"},{"nctId":"NCT04608266","phase":"PHASE3","title":"CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-12-03","conditions":["Covid19"],"enrollment":70,"completionDate":"2021-12-02"},{"nctId":"NCT04374019","phase":"PHASE2","title":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","startDate":"2020-05-01","conditions":["COVID","Sars-CoV2"],"enrollment":13,"completionDate":"2022-01-12"},{"nctId":"NCT04583592","phase":"PHASE2","title":"Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)","status":"COMPLETED","sponsor":"Sagent Pharmaceuticals Inc.","startDate":"2020-11-09","conditions":["COVID-19"],"enrollment":295,"completionDate":"2021-03-31"},{"nctId":"NCT04750759","phase":"PHASE2","title":"Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat","status":"TERMINATED","sponsor":"Charité Research Organisation GmbH","startDate":"2021-02-03","conditions":["Covid19"],"enrollment":4,"completionDate":"2021-10-29"},{"nctId":"NCT04644705","phase":"PHASE1","title":"Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat","status":"COMPLETED","sponsor":"Charité Research Organisation GmbH","startDate":"2020-11-02","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2021-05-03"},{"nctId":"NCT04530617","phase":"PHASE2","title":"Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients","status":"TERMINATED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2020-10-05","conditions":["Covid19","Diabetes","Hypertension","Obesity"],"enrollment":246,"completionDate":"2021-06-10"},{"nctId":"NCT04338906","phase":"PHASE4","title":"Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","status":"WITHDRAWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2020-05","conditions":["COVID"],"enrollment":0,"completionDate":"2021-12"},{"nctId":"NCT04355052","phase":"PHASE3","title":"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-04-11","conditions":["COVID - 19"],"enrollment":250,"completionDate":"2020-12-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018673","UNII":"0FD207WKDU","CHEBI":"CHEBI:135632","INN_ID":"5068","UMLSCUI":"C0129975","ChEMBL_ID":"CHEMBL590799","KEGG_DRUG":"D01766","DRUGBANK_ID":"DB13729","PUBCHEM_CID":"2536","SNOMEDCT_US":"1179628001","IUPHAR_LIGAND_ID":"6432","SECONDARY_CAS_RN":"59721-29-8","MESH_SUPPLEMENTAL_RECORD_UI":"C034532"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":398,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"B02AB04","allCodes":["B02AB04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 7","pmid":"41755626","title":"SARS-CoV-2 infects human primary cytotrophoblasts mainly through a non-canonical entry route.","journal":"Molecular human reproduction"},{"date":"2026 Feb 17","pmid":"41700320","title":"Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.","journal":"The Journal of infectious diseases"},{"date":"2025","pmid":"41601680","title":"SARS-CoV-2 evolution enhances endocytic uptake while preserving TMPRSS2-dependent fusion.","journal":"Frontiers in immunology"},{"date":"2026 Jan 21","pmid":"41596695","title":"A Nasal Spray Combining Camostat with a Natural Polysaccharide for the Prevention of Viral Infection via Nasal Mucosal Barrier Formation and Entry Inhibition.","journal":"International journal of molecular sciences"},{"date":"2026 Jan","pmid":"41319340","title":"Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas.","journal":"ChemMedChem"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","brandName":"CAMOSTAT","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAMOSTAT is a small molecule drug in the camostat class, originally developed by and currently owned by . It targets the serine protease hepsin and is used to treat gastro-esophageal reflux disease with esophagitis. The commercial status of CAMOSTAT is unknown, and it is not FDA-approved. Key safety considerations are not well-documented. CAMOSTAT works by inhibiting the activity of hepsin, a protease involved in inflammation and tissue damage.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}